Preliminary study on rapid identification of Mycobacterium tuberculosis complex isolates by the BD ProbeTec ET system

Wang, S. X.; Sng, Li-Hwei; Tay, L.

doi:10.1099/jmm.0.05454-0

Cited by 10 publications

(9 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…48 Since 2009, a group of investigators have started studying the benefits of rabbit urease breath test for TB diagnosis and treatment monitoring. 48 The specificity of the urease breath test may be increased by introducing intravenous or inhaled 13 C-urea tracer, thus preventing gastric contaminations by Helicobacter species.…”

Section: Sputum Biomarkersmentioning

confidence: 99%

“…Moreover, the performance of NAAT can be compromised under several clinical conditions including inadequate specimens, laboratory contamination, inappropriate processing, and the presence of an amplification inhibitor. [11][12][13][14] Aside from diagnostic advances in the rapid isolation and detection of Mtb, other diagnostic aids for the early identification of TB are needed in view of the aforementioned limitation of current diagnostic tools, and TB can be a lifethreatening disease. For improving TB diagnosis, the role of biomarkers is to provide early suspicion, especially while waiting for the isolation of Mtb or for negative findings of TB suspects ( Figure 1).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Improving tuberculosis diagnostics with biomarkers

Wang¹,

Lee²,

Yu³

et al. 2015

CBF

View full text Add to dashboard Cite

Although many laboratory methods have been developed to expedite the diagnosis of active tuberculosis (TB) and Mycobacterium tuberculosis (Mtb) infection, delays in diagnosis remain a major problem in clinical practice. Biomarkers may contribute favorably or unfavorably to TB diagnosis in a clinical suspect TB case with inconclusive diagnostic findings. A good understanding of the effectiveness and practical limitations of these biomarkers is important to improve diagnosis. This review summarizes currently used biomarkers, mainly as validation, and focuses on latent TB infection, active pulmonary TB, and tuberculous pleural effusion.

show abstract

Section: Sputum Biomarkersmentioning

confidence: 99%

mentioning

confidence: 99%

Improving tuberculosis diagnostics with biomarkers

Wang¹,

Lee²,

Yu³

et al. 2015

CBF

View full text Add to dashboard Cite

show abstract

“…TMC207 sensitivity was analyzed with a Resazurin Microtiter Assay (Institute of Tropical Medicine, Antwerp, Belgium) (20). Mycobacteria were identified with a Mycobacterium tuberculosis Complex Direct Detection assay (Becton Dickinson, Franklin Lakes, NJ; performed by Covance, Geneva, Switzerland) (24).…”

Section: Studymentioning

confidence: 99%

Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis

Rustomjee

Diacon

Allen

et al. 2008

Antimicrob Agents Chemother

249

172

View full text Add to dashboard Cite

Tibotec Medicinal Compound 207 (TMC207) is a novel diarylquinoline with a unique mode of action that targets mycobacterial ATP synthase. TMC207 exhibits high in vitro activity against mycobacterial strains either susceptible or resistant to all first-line and many second-line drugs, including fluoroquinolones, and has shown exceptional in vivo activity against several mycobacterial species in different animal models. In this early bactericidal activity study, 75 treatment-naïve patients with smear-positive pulmonary tuberculosis were randomized to once-daily oral TMC207 (25 mg, 100 mg, or 400 mg), 600 mg rifampin (RIF), or 300 mg isoniazid (INH) for 7 days. Sixteen-hour overnight sputum collected at baseline and on each treatment day was plated in serial dilutions on selective agar plates. The bactericidal activity was expressed as the log 10 decrease in CFU/ml sputum/day. Pharmacokinetic sampling was performed on day 7 of TMC207 administration up to 24 h postdose. The decreases in log 10 CFU counts (؎ standard deviation) from baseline to day 7 were 0.04 ؎ 0.46 for 25 mg TMC207 (n ‫؍‬ 14), 0.26 ؎ 0.64 for 100 mg TMC207 (n ‫؍‬ 14), 0.77 ؎ 0.58 for 400 mg TMC207 (n ‫؍‬ 14), 1.88 ؎ 0.74 for INH (n ‫؍‬ 11), and 1.70 ؎ 0.71 for RIF (n ‫؍‬ 14). Significant bactericidal activity of 400 mg TMC207 was observed from day 4 onward and was similar in magnitude to those of INH and RIF over the same period. The pharmacokinetics of TMC207 were linear across the dose range. In summary, TMC207 demonstrated bactericidal activity with a delayed onset and was well tolerated, and no study drug-related serious adverse events occurred.Tuberculosis (TB) has reemerged as one of the most deadly infectious diseases worldwide, killing approximately 1.7 million people in 2004 (25). In Africa, more than 30% of new adult TB cases are coinfected with human immunodeficiency virus (HIV) (5). Widespread efforts to control the resurgence of TB, such as the implementation of outcome-driven treatment programs (16) and the introduction of "directly observed therapy short-course" (26), have had limited success, in part due to constrained public health resources and the length of treatment needed to sterilize infectious TB lesions. The global situation is deteriorating further with the spread of multidrugresistant (MDR) TB (7, 8) and, more recently, extensively drug-resistant TB (9). There is an urgent need for new anti-TB agents that can shorten treatment duration and are effective in treating drug-sensitive, drug-resistant, and latent TB infection (22).Tibotec Medicinal Compound 207 (TMC207) (also known as R207910) belongs to a newly identified chemical class with antimycobacterial properties. TMC207 demonstrates unique and specific antimycobacterial activity by inhibiting the oligomeric and proteolipic subunit c of mycobacterial ATP synthase, a critical enzyme in the synthesis of ATP (17). Binding of TMC207 to subunit c leads to inhibition of ATP synthesis, which subsequently results in bacterial death. In vitro mycobacterial susceptibility experimen...

show abstract

“…In the study by Wang et al (10) for comparing the BD ProbeTect with NAP test to differentiate M. tuberculosis complex from non-tuberculosis myobacteria, the sensitivity of the ProbeTec system in determining M. tuberculosis complex was reported as 97.8%.…”

Section: Discussionmentioning

confidence: 99%

Comparison of Culture, Real-Time DNA Amplification Assay and Ehrlich-Ziehl-Neelsen for Detection of Mycobacterium tuberculosis

Karadağ¹,

Usta²,

Bılgın³

et al. 2013

Balkan Med J

View full text Add to dashboard Cite

Objective: Mycobacterium tuberculosis is still a substantial health problem universally. Although culture is the gold standard method, reliable, rapid and new methods are required for effective struggle with disease. We retrospectively compared the results of Ehrlich-Ziehl-Neelsen (EZN) stain and real-time DNA amplification assay (BD ProbeTec ET system) with culture.Study Design: Retrospective study. Results: For pulmonary specimens, sensitivity, specificity, positive predictive and negative predictive values of BD ProbeTec ET and EZN were calculated to be 100%, 98.8%, 87.5%, 100% and 71.4%, 98.8%, 83.3%, 97.6%, respectively. For extra pulmonary specimens, sensitivity, specificity, positive predictive and negative predictive values of BD ProbeTec ET and EZN were calculated to be 80%, 98.7%, 76.9%, 98.9% and 24%, 98.3%, 42.8%, 96.2%, respectively. Conclusion:According to these results, we suggest that the BD ProbeTec ET system is more reliable than EZN. In addition, the BD ProbeTec ET system produces faster results. Based upon these results, we consider that the BD ProbeTec ET system may be employed in the diagnosis of M. tuberculosis.

show abstract

Preliminary study on rapid identification of Mycobacterium tuberculosis complex isolates by the BD ProbeTec ET system

Cited by 10 publications

References 13 publications

Improving tuberculosis diagnostics with biomarkers

Improving tuberculosis diagnostics with biomarkers

Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis

Comparison of Culture, Real-Time DNA Amplification Assay and Ehrlich-Ziehl-Neelsen for Detection of Mycobacterium tuberculosis

Contact Info

Product

Resources

About